Targeted Alpha Therapy: Exploring the Clinical Insights into [225Ac]Ac-PSMA and Its Relevance Compared with...

Area of Science:

• Nuclear Medicine
• Oncology
• Radiopharmaceutical Therapy

Background:

• Targeted alpha therapy (TAT) is emerging for metastatic castration-resistant prostate cancer (mCRPC).
• Actinium-225 labelled prostate-specific membrane antigen ([225Ac]Ac-PSMA) offers potent, localized cytotoxic effects due to high linear energy transfer.
• [225Ac]Ac-PSMA is being evaluated against beta-emitter therapy, such as lutetium-177 ([177Lu]Lu-PSMA).

Purpose of the Study:

• To review current clinical evidence on [225Ac]Ac-PSMA radioligand therapy (RLT) for mCRPC.
• To assess the efficacy and safety of [225Ac]Ac-PSMA compared to [177Lu]Lu-PSMA.
• To identify challenges and future directions for [225Ac]Ac-PSMA adoption.

Main Methods:

• Review of compassionate-use programs and small clinical trials involving [225Ac]Ac-PSMA.
• Analysis of biochemical and imaging response data.
• Evaluation of safety profiles, including adverse events like xerostomia and renal toxicity.

Main Results:

• [225Ac]Ac-PSMA demonstrates significant prostate-specific antigen (PSA) declines and lesion regression in heavily pre-treated mCRPC patients.
• Efficacy is observed even in cases of beta-refractory disease, suggesting a complementary role to [177Lu]Lu-PSMA.
• Key safety concerns include xerostomia, renal toxicity, and hematological adverse effects, requiring optimized patient selection and management.

Conclusions:

• [225Ac]Ac-PSMA RLT is a promising treatment for mCRPC, showing notable efficacy.
• Safety challenges necessitate careful patient management and further research into protective strategies.
• Limited availability, high costs, and lack of large trials impede widespread clinical use, highlighting the need for future research and development.